Most Recent

Mail

By | January 1, 2011

A selection of comments from our readers

0 Comments

image: Watt Fun!

Watt Fun!

By | January 1, 2011

Her doctoral advisor told her to amuse herself, and Fiona Watt has done just that—probing individual stem cells and determining the genes and molecules that direct them to differentiate or cause them to contribute to cancer.

3 Comments

image: Myc, Nicked

Myc, Nicked

By | January 1, 2011

Editor's Choice in Developmental Biology

0 Comments

image: The Profits of Nonprofit

The Profits of Nonprofit

By | January 1, 2011

The surprising results when drug development and altruism collide

9 Comments

image: Jeremy Reiter: Hunting for Cilia

Jeremy Reiter: Hunting for Cilia

By | January 1, 2011

Assistant professor of biochemistry, University of California, San Francisco. Age: 39

3 Comments

image: Book Excerpt from <em>Looking for a Few Good Males</em>

Book Excerpt from Looking for a Few Good Males

By | January 1, 2011

In Chapter 2, "Progressive Desire," author Erika Lorraine Milam explores sexual selection’s incursion into evolutionary theory.

0 Comments

image: Capsule Reviews

Capsule Reviews

By | January 1, 2011

How to Catch a Robot Rat, On Fact and Fraud, Not a Chimp, Here Is a Human Being

0 Comments

Popular Now

  1. How Gaining and Losing Weight Affects the Body
    Daily News How Gaining and Losing Weight Affects the Body

    Millions of measurements from 23 people who consumed extra calories every day for a month reveal changes in proteins, metabolites, and gut microbiota that accompany shifts in body mass.

  2. That Other CRISPR Patent Dispute
    Daily News That Other CRISPR Patent Dispute

    The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

  3. Neurons Use Virus-Like Proteins to Transmit Information
  4. EPO Revokes Broad’s CRISPR Patent
    The Nutshell EPO Revokes Broad’s CRISPR Patent

    Shortly after ruling out the earliest priority dates on a foundational patent for CRISPR gene-editing technology, the European Patent Office rescinded the patent entirely—and more are likely to follow.

AAAS